Quarterly results
consolidated · as filed with NSE · Q1 FY27 back to Q1 FY27
| ₹ crore | Q1 FY27 |
|---|---|
| Revenue from operations | 122 |
| Other income | 4.4 |
| Total expenses | 112 |
| EBITDA | 18.1 |
| EBITDA margin | 14.8% |
| Finance costs | 2.5 |
| Depreciation | 5.2 |
| Profit before tax | 14.7 |
| Tax | 5.2 |
| Net profit | 9.5 |
| Net margin | 7.8% |
| EPS (₹) | 3.40 |
Annual results
financial years ending March · from the fourth-quarter filingsNo annual results on record.
EPS is as filed for each period and is not restated for later bonus issues or splits.
Result filings
as filed with NSE · PDF and XBRLKey ratios
P/E (TTM)–
P/B–
ROE–
Net margin–
Debt / equity–
Revenue CAGR (3Y)–
Profit CAGR (3Y)–
EPS (TTM)–
Market cap–
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
Revenue mix Q1 FY27
Bulk drugs/chemicals98.3%result ₹19.1 Cr
Property (Refer Note 4)1.7%result ₹0.1 Cr
Segment revenue as reported, before inter-segment eliminations.